Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Phase 1

Active, not recruiting

• Conditions: Lymphoplasmacytic Lymphoma
• Interventions: Biological: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine; Other: Laboratory Biomarker Analysis

• Registration Number: NCT01209871
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate the safety and feasibility of using a novel lymphoma deoxyribonucleic acid (DNA) vaccine encoding macrophage inflammatory protein 3 alpha (MIP3a)-fused lymphoma idiotype in single chain format.

II. To determine the maximum tolerated dose (MTD) of the vaccine.

SECONDARY OBJECTIVES:

I. To assess the immunogenicity of the vaccine to generate tumor-specific cellular and humoral immune responses.

OUTLINE: This is a dose-escalation study.

Patients receive autologous lymphoma immunoglobulin-derived single-chain variable fragment (scFV)-chemokine DNA vaccine intradermally (ID) at 0, 4, and 8 weeks.

After completion of study treatment, patients are followed up at 4 weeks, and then every 6 months for 1 year.

Study Timeline

• Study First Submitted: 2010-09-24
• Study First Submitted QC: 2010-09-24
• Study First Posted: 2010-09-27
• Study Start: 2015-02-26
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-08
• Last Update Posted: 2025-01-10
• Primary Completion: 2026-02-20
• Study Completion: 2026-02-20

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

• Tissue diagnosis of lymphoplasmacytic lymphoma with surface immunoglobulin G (IgG), immunoglobulin A (IgA) or immunoglobulin M (IgM) phenotype with a monoclonal heavy and light chain as determined by flow cytometry; all primary diagnostic lymph node and/or bone marrow biopsies will be reviewed at the University of Texas M.D. Anderson Cancer Center (UTMDACC)
• Previously untreated patients with lymphoplasmacytic lymphoma (of any subtype: IgG, IgA, IgM) in the asymptomatic phase
• Patients must provide a lymph node sample of at least 1.5 cm in the long axis, or a bone marrow aspiration sample providing at least 5 million cluster of differentiation (CD)20 and/or CD38+ (approximately 10 ml)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Serum creatinine =< 1.5 mg/dl and a creatinine clearance >= 30 ml/min
• Total bilirubin =< 1.5 mg/dl unless felt secondary to Gilbert's disease
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x upper limit of normal
• Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires
• Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 30 days after the last vaccination has been administered
• Male subject agrees to use an acceptable method for contraception for the duration of the study

Exclusion Criteria

• Human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C infection
• Pregnancy or lactating females
• Patients with previous history of malignancy within the last 5 years except curatively treated squamous or basal cell carcinoma of the skin or curatively treated carcinoma in-situ of other organs
• Any medical or psychiatric condition that in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment
• Patients with New York Heart Association class 3 or 4 disease
• Patients with a history of autoimmune diseases except for Hashimoto's thyroiditis
• Patients with positive antinuclear antibody (ANA) and/or anti-double strand (ds) DNA antibodies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (vaccine therapy)	Laboratory Biomarker Analysis	Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.
Treatment (vaccine therapy)	Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine	Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity according to the National Cancer Institute Common Toxicity Criteria version 4.0	4 weeks	Toxicity type and severity will be summarized by frequency tables.

Secondary Outcome Measures

Name	Time	Method
Immune response defined as at least a three-fold rise in the precursor frequency of tumor-reactive T cells	At 12 weeks	The rate of immune response will be estimated.

Trial Locations

Locations (1)

M D Anderson Cancer Center; 🇺🇸 Houston, Texas, United States